1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.11
D/E ratio at 50-90% of Drug Manufacturers - Specialty & Generic median of 0.15. Peter Lynch would verify if this conservative capital structure supports growth opportunities.
14.44
Dangerously high net debt exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.52. Michael Burry would check for debt covenant compliance and refinancing risks.
-0.92
Negative coverage while Drug Manufacturers - Specialty & Generic median is 0.00. Seth Klarman would scrutinize operating performance and look for turnaround catalysts.
2.27
Current ratio near Drug Manufacturers - Specialty & Generic median of 2.13. David Dodd would examine if industry-standard liquidity is appropriate given business model.
67.45%
Intangibles exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 11.26%. Michael Burry would check for aggressive accounting and hidden risks.
